What FDA’s blue-light cystoscopy reclassification could mean for Photocure and Cysview
FDA’s Class II proposal could lower a major equipment barrier for Photocure’s Cysview. See what the regulatory shift could mean for US adoption.
Medical Devices & Diagnostics